GSK
727 hedge funds and large institutions have $8.39B invested in GSK in 2016 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 274 increasing their positions, 251 reducing their positions, and 49 closing their positions.
53% more call options, than puts
Call options by funds: $133M | Put options by funds: $86.8M
41% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 49
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
1% more funds holding
Funds holding: 719 → 727 (+8)
9% more repeat investments, than reductions
Existing positions increased: 274 | Existing positions reduced: 251
0.16% less ownership
Funds ownership: 3.54% → 3.39% (-0.16%)
4% less capital invested
Capital invested by funds: $8.7B → $8.39B (-$307M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$89.2M |
| 2 |
OCM
Osterweis Capital Management
San Francisco,
California
|
+$41.4M |
| 3 |
Goldman Sachs
New York
|
+$39M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$34.6M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$32.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$127M |
| 2 |
Primecap Management
Pasadena,
California
|
-$125M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$110M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$95.5M |
| 5 |
JP Morgan Chase
New York
|
-$82.3M |
GSK Hedge Fund Activity: Q1 2016 in Review
727 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2016, worth a combined $8.39B — down 3.5% from $8.7B a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new GSK positions and 49 closed out — a net gain of 20 holders — while 274 added to existing stakes and 251 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $89.2M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $127M.
- 727 institutional investors held GSK (GSK) as of Q1 2016, up from 719 in Q4 2015.
- Funds reported $8.39B of GSK stock for Q1 2016, down 3.5% quarter-over-quarter.
- 69 funds opened new GSK positions in Q1 2016 and 49 closed out, a net change of +20 holders.
- The largest GSK buyer in Q1 2016 was Fidelity Investments, an estimated $89.2M added.
- The largest GSK seller in Q1 2016 was Hotchkis & Wiley Capital Management, an estimated $127M sold.
Based on aggregated 13F filings for Q1 2016.